Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Laura Newman  |  January 21, 2016

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Cancercervical cancerRheumatoid Arthritis (RA)TNFTNF inhibitorstumor necrosis factorWomen

Secukinumab Receives 2 New Approvals: PsA & AS

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2016

The FDA approved secukinumab (Cosentyx) this past week for the treatment of adults with active ankylosing spondylitis and active psoriatic arthritis. These two new approvals are based on the safety and efficacy outcomes from four placebo-controlled Phase 3 trials in more than 1,500 adults with AS or PsA…

Filed under:Biologics/DMARDsDrug Updates

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2016

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:adalimumabCanadaChronic painchronic pruritushiphip painInternationalKnee Osteoarthritis (OA)olokizumabOsteoarthritisPainRheumatoid Arthritis (RA)

French ‘Cannabis’ Drug Trial Volunteer Dies

Reuters Staff  |  January 19, 2016

RENNES, France (Reuters)—A man left brain dead after a drug trial in northwest France died on Sunday, said the hospital where he was being treated. The Rennes hospital said in a statement that five other volunteers were in stable condition after they were admitted last week. In total, 90 people took part in the trial of the drug made…

Filed under:Drug Updates Tagged with:cannabisclinical trialsDrugsFranceInternationalSafety

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

Mary Beth Nierengarten  |  January 19, 2016

SAN FRANCISCO—“Interstitial lung disease is the last bastion of great medicine,” according to Paul Noble, MD, chair, Department of Medicine, director, Women’s Guild Lung Institute, Vera and Paul Guerin Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles. Making it great medicine, he said, are the many things still unknown about this disease. In…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:AC&RAmerican College of Rheumatology (ACR)Diagnosisfibrosing lung diseaseResearchrheumatology

Search for Infectious Triggers of Rheumatic Disease Could Yield Options to Block Process

Susan Bernstein  |  January 19, 2016

SAN FRANCISCO—Two hundred years ago, physicians knew nothing about what caused various forms of arthritis. Today, we have more clues about what may trigger rheumatic diseases, but still can’t pinpoint the culprits that set scores of inflammatory conditions in motion. Researchers discussed some of the background and recent findings that point to what immunologists call…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:AC&RAmerican College of Rheumatology (ACR)environmentalgeneinflammationResearchRheumatic Diseaserheumatologytrigger

The ACR/ARHP Award Winners Discuss Their Contributions to Rheumatology

Richard Quinn  |  January 19, 2016

At the 2015 ACR/ARHP Annual Meeting in San Francisco in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. In the December 2015 issue, The Rheumatologist reported on the ACR’s awards. This month, we speak with the ARHP winners about…

Filed under:AwardsCareer DevelopmentProfessional Topics Tagged with:ACR/ARHPAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)Awardswinner

Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Louise Grech, BPharm (Hons), MPhil, MRPharmS, Victor Ferrito, BSc, MSc, PhD, CSci, Liberato Camilleri, BEd, MSc, PhD, Anthony Serracino Inglott, BPharm, PharmD, MRPharmS, & Lilian M. Azzopardi, BPharm (Hons), MPhil, PhD, MRPharmS  |  January 19, 2016

Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Drugspatient carepharmaceuticalRheumatoid arthritistherapyTreatment

How to Choose the xBest Course of Treatment to Manage Rheumatoid Arthritis

How to Choose the Best Course of Treatment to Manage Rheumatoid Arthritis

Karen Appold  |  January 19, 2016

Diagnosing rheumatoid arthritis (RA) early in the disease process is ideal, because treatments are more likely to be effective and less damage will occur. Guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) state that using newer biologic medications, in addition to more aggressive dosing of traditional medications, is…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Managementpatient careRheumatoid arthritistherapyTreatment

  • « Previous Page
  • 1
  • …
  • 223
  • 224
  • 225
  • 226
  • 227
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences